2025-07-11 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc (RXRX), incorporating the provided data and formatted as requested.

## RXRX: Recursion Pharmaceuticals Inc. Analysis

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering.

### 1. Performance vs. S&P 500 (VOO)

*   **Accumulated Return RXRX:** -47.12%
*   **Accumulated Return VOO:** 35.27%
*   **Divergence:**
    *   Current: -81.8
    *   Range: Max 35.8, Min -88.1
    *   Relative Divergence: 5.1

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO). The current divergence is -81.8, placing it near the bottom of its historical range relative to the S&P 500. The Relative Divergence of 5.1 indicates that the underperformance is near its worst levels compared to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2021-2023  | 5.0%  | 73.6% | -1.0%  | -0.1 | 4.3    |
| 2022-2024  | 0.0%  | 73.6% | -25.0% | 0.1  | 2.9    |
| 2023-2025  | 4.0%  | 73.6% | -44.0% | 0.1  | 2.5    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate is relatively low across all periods, showing inconsistent growth.
*   **MDD:** The Maximum Drawdown is very high (73.6%) across all periods, indicating significant risk and volatility.
*   **Alpha:** Alpha is negative and decreasing over time, indicating underperformance relative to the market.
*   **Beta:** Beta is very low (close to 0), suggesting that the stock's price movements are not strongly correlated with the overall market.

### 2. Recent Stock Price Movements

*   **Current Price:** $5.715
*   **Previous Close:** $5.59 (Change: +2.24%)
*   **5-day Moving Average:** 5.4289
*   **20-day Moving Average:** 5.1827
*   **60-day Moving Average:** 4.9918

**Analysis:** The stock price is currently above its 5, 20, and 60-day moving averages, indicating a short-term upward trend. The +2.24% change from the previous close suggests a recent positive price movement, reflecting a possible surge or recovery.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3373 (Low Risk)
*   **RSI:** 60.79
*   **PPO:** 0.981
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** +4.9 (Short-term Increase)
*   **Expected Return:** -479.5%

**Analysis:**

*   The MRI indicates Low Risk, which is contradictory to the high volatility shown in the Alpha/Beta analysis.
*   The RSI suggests that the stock is approaching overbought territory.
*   The positive PPO indicates a bullish trend.
*   The Hybrid Signal suggests a cautious buying approach.
*   The recent increase in relative divergence indicates short-term upward momentum compared to the S&P 500.
*   The **very large negative expected return (-479.5%)** suggests that, based on the model, the stock is significantly overvalued or has very poor future prospects compared to the S&P 500, even with a long-term investment horizon.

### 4. Recent News & Significant Events

*   **[2025-07-08]:** Recursion Pharmaceuticals Inc (RXRX) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-07-07]:** Analysts are discussing Recursion Pharmaceuticals Inc's (RXRX) recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-07-10]:** Recursion Pharmaceuticals Inc (RXRX)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-11]:** Market experts highlight both risks and opportunities for Recursion Pharmaceuticals Inc (RXRX), advising investors to monitor recent news and company announcements.

**Analysis:** Recent news indicates that RXRX is experiencing significant events and high volatility. Investors should closely monitor the company's announcements and market news.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-05 | -0.5  | 0.01 B$     |
| 2024-11-06 | -0.34 | 0.03 B$     |
| 2024-08-08 | -0.4  | 0.01 B$     |
| 2024-05-09 | -0.39 | 0.01 B$     |
| 2025-05-05 | -0.39 | 0.01 B$     |

**Analysis:** The company consistently reports negative Earnings Per Share (EPS), which indicates a lack of profitability. Revenue is relatively low and inconsistent.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |
| 2024-03-31 | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |
| 2024-06-30 | $0.58B  | -16.69%  |
| 2024-03-31 | $0.40B  | -22.78%  |

**Analysis:**

*   **Revenue:** Fluctuating revenue indicates inconsistency in business performance.
*   **Profit Margin:** The profit margins are highly volatile and often negative, especially in the most recent quarter, which raises concerns about the company's ability to manage costs.
*   **Equity:** Equity is fluctuating significantly, which suggests instability in the company's financial structure.
*   **ROE:** Negative Return on Equity (ROE) indicates the company is not generating profits from shareholders' investments, further reinforcing profitability concerns.

### 7. Overall Analysis

RXRX has significantly underperformed the S&P 500. While there's a recent short-term upward trend in the stock price, the company shows significant financial concerns.

*   **Negative Profitability:**  Consistently negative EPS, fluctuating revenues, and negative profit margins are major red flags.
*   **High Volatility:** The stock exhibits high volatility and a large maximum drawdown, indicating significant risk.
*   **Negative Expected Return:** The very negative expected return (-479.5%) suggests the stock is significantly overvalued based on the model used.
*   **Conflicting Signals:** While the MRI suggests low risk, the high volatility and negative profitability paint a different picture.
*   **Recent News:** The company is undergoing significant events, but the details are necessary to determine whether these events could improve or worsen the company's outlook.

**Conclusion:** Based on the provided data, RXRX appears to be a high-risk investment with poor historical performance and significant financial challenges. Investors should exercise extreme caution and conduct further thorough research before considering an investment in this company.
